203 related articles for article (PubMed ID: 38277059)
21. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.
Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS
AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259
[TBL] [Abstract][Full Text] [Related]
22. Radiomics in gliomas: A promising assistance
for glioma clinical research.
Leng Y; Wang X; Liao W; Cao Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 43(4):354-359. PubMed ID: 29774870
[TBL] [Abstract][Full Text] [Related]
23. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
[TBL] [Abstract][Full Text] [Related]
24. Adult IDH wild-type lower-grade gliomas should be further stratified.
Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
[TBL] [Abstract][Full Text] [Related]
25. Multimodel habitats constructed by perfusion and/or diffusion MRI predict isocitrate dehydrogenase mutation status and prognosis in high-grade gliomas.
Liu J; Cong C; Zhang J; Qiao J; Guo H; Wu H; Sang Z; Kang H; Fang J; Zhang W
Clin Radiol; 2024 Jan; 79(1):e127-e136. PubMed ID: 37923627
[TBL] [Abstract][Full Text] [Related]
26. Clinical Laboratory Testing Practices in Diffuse Gliomas Prior to Publication of 2021 World Health Organization Classification of Central Nervous System Tumors.
Ramkissoon SH; Fernandes H; Lopez-Terrada DH; Hameed MR; Trembath DG; Bridge JA; Lindeman NI; Souers RJ; Vasalos P; Brat DJ; Moncur JT
Arch Pathol Lab Med; 2022 May; 147(5):518-524. PubMed ID: 35878398
[TBL] [Abstract][Full Text] [Related]
27. WHO CNS5 2021 includes specific mutations in gliomas that can be identified with MRI quantitative biomarkers.
García-Lezama M; Carrillo-Ruiz JD; Moreno-Jiménez S; Roldán-Valadez E
Gac Med Mex; 2023; 159(2):161-168. PubMed ID: 37094238
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
29. The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 3-Summary of Imaging Findings on Glioneuronal and Neuronal Tumors.
Park YW; Vollmuth P; Foltyn-Dumitru M; Sahm F; Choi KS; Park JE; Ahn SS; Chang JH; Kim SH
J Magn Reson Imaging; 2023 Dec; 58(6):1680-1702. PubMed ID: 37715567
[TBL] [Abstract][Full Text] [Related]
30. Updates on the WHO diagnosis of IDH-mutant glioma.
Reuss DE
J Neurooncol; 2023 May; 162(3):461-469. PubMed ID: 36717507
[TBL] [Abstract][Full Text] [Related]
31. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
[TBL] [Abstract][Full Text] [Related]
32. Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics.
Bahrami N; Hartman SJ; Chang YH; Delfanti R; White NS; Karunamuni R; Seibert TM; Dale AM; Hattangadi-Gluth JA; Piccioni D; Farid N; McDonald CR
J Neurooncol; 2018 Sep; 139(3):633-642. PubMed ID: 29860714
[TBL] [Abstract][Full Text] [Related]
33. Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review.
Lasocki A; Abdalla G; Chow G; Thust SC
Cancer Imaging; 2022 Nov; 22(1):63. PubMed ID: 36397143
[TBL] [Abstract][Full Text] [Related]
34. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and Predictive Biomarkers in Gliomas.
Śledzińska P; Bebyn MG; Furtak J; Kowalewski J; Lewandowska MA
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638714
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion-weighted MRI models.
Guo H; Liu J; Hu J; Zhang H; Zhao W; Gao M; Zhang Y; Yang G; Cui Y
J Magn Reson Imaging; 2022 Dec; 56(6):1834-1844. PubMed ID: 35488516
[TBL] [Abstract][Full Text] [Related]
37. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
[TBL] [Abstract][Full Text] [Related]
38. Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.
Di Stefano AL; Enciso-Mora V; Marie Y; Desestret V; Labussière M; Boisselier B; Mokhtari K; Idbaih A; Hoang-Xuan K; Delattre JY; Houlston RS; Sanson M
Neuro Oncol; 2013 May; 15(5):542-7. PubMed ID: 23161787
[TBL] [Abstract][Full Text] [Related]
39. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI.
Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J
Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279
[TBL] [Abstract][Full Text] [Related]
40. Rapid intraoperative multi-molecular diagnosis of glioma with ultrasound radio frequency signals and deep learning.
Xie X; Shen C; Zhang X; Wu G; Yang B; Qi Z; Tang Q; Wang Y; Ding H; Shi Z; Yu J
EBioMedicine; 2023 Dec; 98():104899. PubMed ID: 38041959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]